An AMCP Market Insights Webinar

Join us for a webinar on the managed care approaches to Bispecific Antibodies (BsAbs), focusing on follicular Lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This session will feature clinical managed care participants from the roundtable convened by AMCP in April 2025. Presenters will examine the cost-effectiveness of BsAbs compared to alternative treatment pathways for FL and DLBCL, explore payer perspectives on the role of BsAbs, review clinical trial results and real-world evidence for BsAbs, gain insights into best practices for MCOs in managing BsAbs effectively, and provide an update on the unique science, mechanisms of action and dosing protocols of BsAbs.

An AMCP Webinar, hosted by FormularyDecisions®

In today’s rapidly evolving health care landscape, 89% of health care decision-makers (HCDMs) use digital channels as a key source of information in decision-making. Are you interested in exploring tools to streamline how you gather sources, review drug information, and learn from peer perspectives? Join FormularyDecisions | Cencora, in partnership with AMCP, for an overview of FormularyDecisions®. This online platform streamlines the product review process and provides HCDMs complimentary access to evidence on pipeline and FDA-approved products.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Sanofi.

During this webinar, the burden of disease in patients with MS, the role of BTK inhibition in MS, the mechanism of action of BTK inhibition, and the efficacy and safety results from the HERCULES and GENIMI clinical development program will be discussed. There will be a live Q&A to allow for interactive discussion.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
 

Stay informed and prepared with a Regulatory Briefing, a members-only webinar designed to help managed care pharmacy professionals understand key regulatory developments that may impact your work.

This session breaks down CMS’s newly released draft guidance on the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. You’ll gain clarity on how CMS plans to select drugs for the Initial Price Applicability Year 2028, how the Maximum Fair Price will be implemented, and what’s proposed for negotiation and renegotiation processes. Find out what’s changing, how it could affect you and health care organizations, and how you can contribute to AMCP’s advocacy efforts on this important issue.

A Science and Innovation Webinar, presented by CSL Behring.

CSL Behring is proud to present a webinar highlighting the 4-year milestones for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy approved for hemophilia B. This virtual presentation will explore the clinical and economic value of HEMGENIX® vs the current standard of care – Q&A to follow.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Sydnexis.

The speakers will discuss the rise in prevalence, severity, and irreversible vision threatening co-morbidities associated with myopia. We will explore the latest published data and discuss the primary causes of myopia, both genetic and environmental. We will also examine the significant health impact this epidemic has on patients and caregivers throughout their lives. Finally, the presentation will highlight an investigational Rx treatment for slowing myopic progression in pediatric patients. SYD-101 has an assigned PDUFA date of October 23, 2025.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Apellis Pharmaceuticals, Inc.

C3G and Primary IC-MPGN are 2 rare, chronic glomerular diseases that are driven by complement system overactivation and lead to severe kidney damage. Review of the results of the VALIANT Phase 3 trial, evaluating pegcetacoplan as an investigational product for use in C3G and IC-MPGN. The safety and efficacy of pegcetacoplan in C3G and IC-MPGN have not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.